- dPDT is an effective treatment for field change actinic keratosis (AK).
- dPDT light dose is not routinely monitored due to demanding measurement techniques.
- SmartPDT® is a novel method of delivering dPDT using a smart-phone and web portal.
- SmartPDT® accurately determines light dose received during dPDT without a detector.
- SmartPDT® forecasts expected light dose 24 and 48 h prior to treatment.
Actinic keratosis (AK) affects one quarter of over 60 year olds in Europe with the risk of transforming into invasive squamous cell carcinoma. Daylight photodynamic therapy (dPDT) is an effective and patient preferred treatment that uses sunlight to clear AK. Currently, there is no standardised method for measuring the light received during treatment.
SmartPDT® is a smartphone-based application and web-portal, developed by siHealth Ltd, enabling remote delivery of dPDT. It uses satellite imagery and computational algorithms to provide real-time determination of exposure to PpIX-effective solar radiation (“light dose”). The application also provides forecast of expected radiant exposures for 24- and 48-hs prior to the treatment period. Validation of the real-time and forecasted radiant exposure algorithms was performed against direct ground-based measurement under all weather conditions in Chilton, UK.
Agreement between direct ground measurements and satellite-determined radiant exposure for 2-h treatment was excellent at −0.1 % ± 5.1 % (mean ± standard deviation). There was also excellent agreement between weather forecasted radiant exposure and ground measurement, 1.8 % ± 17.7 % at 24-hs and 1.6 % ± 25.2 % at 48-hs. Relative Root Mean Square of the Error (RMSEr) demonstrated that agreement improved as time to treatment reduced (RMSEr = 22.5 % (48 -hs), 11.2 % (24-hs), 5.2 % (real-time)).
Agreement between satellite-determined, weather-forecasted and ground-measured radiant exposure was better than any existing published literature for dPDT. The SmartPDT® application and web-portal has excellent potential to assist with remote delivery of dPDT, an important factor in reducing risk in an elderly patient population during the Covid-19 pandemic.
Luke J. McLellana, Marco Morellib, Emilio Simeoneb, Marina Khazovac, Sally H. Ibbotsona,d,e and Ewan Eadied
- aSchool of Medicine, University of Dundee, DD1 9SY, UK
- bsiHealth Ltd, Building R104, RAL, Harwell Campus, Didcot, OX11 0QX, UK
- cPublic Health England, Didcot, OX11 0RQ, UK
- dThe Scottish Photodynamic Therapy Centre, Ninewells Hospital, Dundee, DD1 9SY, UK
- ePhotobiology Unit, NHS Tayside, Ninewells Hospital, Dundee, DD1 9SY, UK